Compounded HRT vs FDA-Approved: What the 'Bioidentical' Label Actually Means

The word “bioidentical” does not mean what the marketing implies.

It does not mean compounded. It does not mean unregulated. It does not mean tested by anyone, in any dose, in any combination. And it does not distinguish compounded pharmacy products from FDA-approved medications that use the same molecules.

The hormone estradiol that is bioidentical is the same chemical compound whether it comes from a Vivelle-Dot transdermal patch manufactured under FDA Good Manufacturing Practice standards or from a compounding pharmacy that mixed it in a jar that morning. The FDA-approved version has documented dose accuracy, batch testing, sterility assurance, and clinical trial evidence. The compounded version has none of these requirements.

This distinction matters clinically, and it is the distinction the marketing is designed to obscure.

How the “bioidentical” marketing was born

To understand why this confusion exists, it helps to know where the word came from. In 2002, the Women’s Health Initiative published results that sent conventional HRT prescribing into a steep decline. The WHI found increased risks of breast cancer, stroke, and cardiovascular events in women taking a specific combination of oral conjugated equine estrogens and a synthetic progestin called medroxyprogesterone acetate (MPA). Within two years, prescriptions for HRT fell by more than fifty percent.

That reaction was understandable. It was also, in significant ways, an overcorrection. The WHI studied a specific formulation in a specific population of women who were, on average, more than a decade past menopause. It did not study transdermal estradiol. It did not study bioidentical progesterone. It did not study younger perimenopausal women. The cardiovascular risk profile of estradiol delivered transdermally in recently menopausal women looks substantially different from the WHI data, as later trials including the KEEPS (Kronos Early Estrogen Prevention Study) and ELITE (Early versus Late Intervention Trial with Estradiol) studies have demonstrated.

Into that vacuum stepped compounding pharmacies with a message calibrated exactly to what frightened women wanted to hear: that there was a different, more natural, more personalized alternative to the synthetic hormones that had caused the problems. That alternative was called “bioidentical.” The framing was clever because it contained a true piece: synthetic progestins like MPA are not bioidentical, and the distinction between bioidentical progesterone and synthetic progestins is pharmacologically real. The sleight of hand was attaching “bioidentical” to the entire compounding pharmacy product line, as though the regulatory status of the pharmacy was part of what made the hormone safer. It was not, and is not.

You are right to have questioned the original WHI findings. The women who pushed back on a blanket “HRT causes cancer” narrative and kept asking for the data were not being difficult. They were reading more carefully than most of their physicians. The conclusion that compounded HRT is the answer to the WHI’s limitations, though, does not follow from the evidence. The answer to flawed data on one specific formulation is better data on better formulations, not an exit from the regulatory system entirely.

What “bioidentical” actually means

Bioidentical refers to the molecular structure of a hormone: a hormone is bioidentical if it is chemically identical to the hormone produced endogenously by the human body. 5 / Solid

By this definition:

• Estradiol (17-beta estradiol) is bioidentical whether it comes in a patch, gel, oral tablet, or vaginal ring
• Micronized progesterone (Prometrium) is a bioidentical FDA-approved progesterone
• Medroxyprogesterone acetate (MPA, the progestin in many older HRT formulations) is NOT bioidentical. It is a synthetic progestin with a different molecular structure.

The bioidentical/non-bioidentical distinction is clinically meaningful: bioidentical progesterone (micronized progesterone) has a different cardiovascular, metabolic, and sleep profile than synthetic progestins like MPA. This is a real pharmacological difference worth discussing with a prescribing physician.

What it does not mean is that compounded products are inherently preferable to FDA-approved bioidentical formulations, or that the word “bioidentical” on a compounding pharmacy label confers any additional safety or clinical advantage.

The regulatory difference

FDA-approved hormone therapies:

• Must demonstrate safety and efficacy in clinical trials before market approval
• Are manufactured under Good Manufacturing Practice (GMP): standardized facilities, equipment, procedures, and documentation
• Have independently verified dose accuracy (the stated dose is what the product contains)
• Are subject to ongoing FDA post-market surveillance, including mandatory adverse event reporting
• Can be recalled if quality problems are identified

Compounded hormone therapies:

• Are exempt from FDA pre-market approval requirements
• Are not required to demonstrate efficacy before dispensing
• Must comply with USP standards at the state pharmacy board level, with oversight that varies significantly by state
• Are not subject to the same batch testing or dose verification requirements
• Have no mechanism equivalent to FDA recall if quality problems emerge at a single pharmacy

This is not a theoretical regulatory distinction. At the FDA Pharmacy Compounding Advisory Committee meeting in 2019, investigators presented findings from quality testing of compounded hormone preparations sampled from multiple pharmacies. Dose variability well outside acceptable pharmaceutical standards was documented. One analysis found that compounded testosterone and estradiol preparations frequently fell outside a 10% variance threshold that would be mandatory for any FDA-approved product. A compounded progesterone capsule labeled 100mg may contain substantially more or less. In FDA-approved Prometrium, it will not. 5 / Solid

The North American Menopause Society (NAMS) 2022 position statement on hormone therapy addressed compounded products directly. The statement concluded that compounded bioidentical hormones should not be used preferentially over FDA-approved therapies because they lack evidence of safety and efficacy, have variable purity and potency, and are not subject to the same regulatory protections. NAMS specifically noted that the absence of standardized manufacturing increases risk rather than reducing it, and that marketing claims about customization and naturalness are not clinically validated.

The cardiovascular evidence gap

This is the piece that almost no one mentions, including the wellness clinic physicians writing compounded prescriptions.

The clinical trials that inform what we know about HRT and cardiovascular outcomes used FDA-approved formulations. The WHI used oral conjugated equine estrogens and MPA. The KEEPS trial used oral conjugated equine estrogens and transdermal estradiol, both FDA-approved. The ELITE trial used oral estradiol, an FDA-approved formulation. The observational data on cardiovascular benefit from estrogen initiated in younger women comes from studies of FDA-approved products.

There are no randomized controlled trials showing cardiovascular safety or benefit for compounded HRT preparations. Not a single one. When a physician cites the ELITE trial’s finding that women who start estradiol within six years of menopause show slower progression of carotid intima-media thickness than those who start later, she is citing data from an FDA-approved oral estradiol product. If she then writes a prescription for a compounded estradiol cream, she is extrapolating across a regulatory and quality gap that the evidence does not bridge.

This matters for a woman trying to make an informed decision. If her physician says “estrogen is cardioprotective when started early in menopause, so I am starting you on this compounded cream,” she is being given a conclusion drawn from one set of products while receiving a different set of products. The pharmacology of estradiol is similar across formulations, but the dose she is actually getting, the absorption profile of the specific compounded preparation, and the purity of the product have not been tested against any cardiovascular endpoint. She is not inside the evidence base her physician is citing. 5 / Solid

This gap matters even more for women with established cardiovascular risk factors. Heart disease is the leading cause of death in women. The timing and formulation of HRT in a woman with hypertension, dyslipidemia, or a family history of early coronary artery disease are not trivial questions. The answers, such as they are, come from trials of FDA-approved products.

Estriol: the unproven third estrogen

Many compounded hormone preparations include estriol (E3), a weaker estrogen that is the predominant estrogen of pregnancy. Estriol is not approved by the FDA in any systemic formulation in the United States.

Proponents argue estriol is safer than estradiol based on its weaker receptor binding. This theoretical safety argument has not been tested in clinical trials with adequate follow-up. In particular:

• Estriol’s effects on breast tissue with long-term systemic use are not established
• Estriol’s cardiovascular effects at the doses used in compounded “tri-est” preparations are not established
• The FDA has not approved estriol for systemic hormone therapy, meaning there is no regulatory-reviewed safety and efficacy data for this use

Women using “tri-est” (estriol + estradiol + estrone combination) compounds are taking a systemic hormone that has not been reviewed for safety by any regulatory body. This is presented as a conservative, more natural choice. The evidence basis for that characterization does not exist. 5 / Solid

Pellet therapy

Subcutaneous pellet therapy involves small hormone implants inserted under the skin that release hormones over three to six months. These are almost universally delivered through compounding pharmacies because FDA-approved pellet formulations do not exist in the United States.

This means women choosing pellet therapy are, by definition, choosing compounded hormone delivery with all the quality control limitations described above. Additionally:

• Pellet dose cannot be adjusted after insertion without another procedure
• Supraphysiological testosterone levels are common in women receiving pellets, particularly with testosterone pellets, because dosing is imprecise
• Removal is not straightforward if a woman has a side effect or wants to stop

Pellets are aggressively marketed via direct-to-consumer advertising. The clinical evidence base for pellets is substantially weaker than for transdermal estradiol, particularly for outcomes like bone density and cardiovascular protection. 4 / Promising

Saliva testing and the monitoring problem

The “customization” promise of compounded HRT depends on a specific monitoring method: saliva hormone testing. Compounding pharmacy providers and the wellness clinics that partner with them frequently use saliva panels to measure estradiol, progesterone, testosterone, cortisol, and DHEA, then adjust compounded doses based on those results. The premise sounds rigorous. The problem is that the premise is not supported by evidence.

Saliva hormone levels do not correlate reliably with serum hormone levels or with tissue hormone levels in a clinically validated way. The relationship between salivary estradiol and circulating or tissue estradiol is influenced by diet, hydration, time of day, whether a topical hormone has been applied near the mouth, and individual variation in salivary gland function. A high salivary estradiol result may reflect contamination from a topical product applied to the skin near the face rather than systemic estrogen status.

Both the Endocrine Society and NAMS have stated explicitly that salivary hormone testing is not a reliable method for monitoring systemic hormone therapy. The Endocrine Society’s clinical practice guidelines on hormone therapy note that serum testing is the appropriate method for monitoring systemic estrogen and testosterone levels, and that salivary testing introduces variability that cannot be clinically interpreted with confidence.

The customization offered by compounded HRT is therefore built on a two-step problem: a testing method that the relevant endocrinology bodies consider unreliable, feeding into a product with dose accuracy that no independent body has verified. The promise of personalization is real in concept. The execution does not currently deliver it. 5 / Solid

When compounded HRT is clinically appropriate

Compounded HRT has a legitimate role in specific circumstances:

Excipient allergy. If a woman has a documented allergy to an inactive ingredient in all available FDA-approved formulations, a compounding pharmacy can prepare the same active hormone without the problematic excipient.

Unavailable dose. If the clinically appropriate dose falls between available FDA-approved formulations (for example, a dose lower than any commercial patch), compounding can provide that dose, though FDA formulations now cover a wide dose range.

Specific delivery route. Certain delivery routes are not commercially available for some hormones. Testosterone is not FDA-approved for women in the United States; a low-dose compounded topical testosterone cream may be appropriate in specific clinical circumstances.

These are narrow, physician-determined indications. The routine preference for compounded HRT based on marketing claims of “customization,” “natural” origins, or superior safety is not a clinical indication.

What to do this week

If a physician recommends compounded HRT, appropriate questions include:

“Is there an FDA-approved formulation of this hormone that would meet my clinical needs?”

“What specific clinical reason makes a compounded preparation necessary for me?”

“What quality certification does this compounding pharmacy have?” (PCAB, the Pharmacy Compounding Accreditation Board, accreditation is a meaningful quality indicator for compounding pharmacies.)

“If I am prescribed estriol or a combination not available in any FDA-approved product, what evidence supports its safety?”

These questions are not adversarial. They are the same questions a prescribing physician should be asking.

If you are already taking compounded HRT and wondering what to do next, here are three concrete steps:

Get serum levels tested. Regardless of what saliva testing showed, ask your physician to order serum estradiol, progesterone (if applicable), and testosterone. These results give a more reliable picture of what is actually circulating. High or very low serum levels may indicate that your compounded dose is not delivering what the label states.

Ask specifically about switching to FDA-approved equivalents. In most cases, transdermal estradiol (patch or gel) and micronized progesterone (Prometrium) can replace a compounded estradiol-progesterone preparation without loss of clinical benefit and with substantially better dose certainty. If your physician says there is no FDA-approved equivalent, ask which specific ingredient requires compounding.

If you are on estriol or “tri-est,” have a direct conversation about the evidence. Ask your physician for the clinical trial data supporting estriol’s safety profile for systemic use in postmenopausal women. If the answer is references to theoretical receptor binding or smaller observational studies rather than a randomized trial, you now know the actual evidence basis for what you are taking.

Related reading

For the HRT formulation comparison (oral vs transdermal vs vaginal): HRT Formulation: Oral vs Transdermal vs Vaginal.

For the perimenopause context and what drives HRT decisions: What Is Really Happening at Perimenopause.

For the complete perimenopausal cardiac workup: The Five Numbers That Define Your Cardiac Baseline.